Based on these findings, we suggest using SGLT-2 inhibitors for cardiovascular and renal protection in patients with CKD and maintaining this treatment as kidney function declines until initiation of renal replacement therapy. This evidence concerns the gene SLC5A2 and chronic kidney disease.